Wouter Sebastian Johannes Joustra
Independent Non-Executive DirectorMr. Wouter Sebastian Johannes Joustra, M.Sc., serves as General Partner of Forbion Capital Partners B.V. since July 2020. He joined the firm in October 2019. At the firm, he also served as Partner from October 2019 to July 2020. He is responsible for deal origination, general portfolio management and divestment strategies. He serves as Independent Director at Vor Biopharma Inc. since December 2025. He serves as Director of Verdiva Bio Limited since October 23, 2024. He serves as Director of Navigator Medicines, Inc. since August 2024. He serves as Independent Non-Executive Director of NewAmsterdam Pharma Company N.V. since July 16, 2024. He serves as Independent Non-Executive Director of enGene Therapeutics Inc. since May 15, 2024. He is Investor Director of Beacon Therapeutics (USA), Inc. since 2024. He serves as Director of VectorY Therapeutics B.V. since November 13, 2023. He serves as Director of Gyroscope Therapeutics Limited since March 2021. He is Co-Owner of Forbion Growth Sponsor Feac I B.V. and serves as an Investor Director at Beacon Therapeutics Limited. Mr. Joustra was Board Observer of NewAmsterdam Pharma Company N.V. until July 16, 2024. He was Director of Aiolos Bio, Inc. until February 2024. He was an Independent Director of VectivBio Holding AG from December 9, 2022 until December 2023. He was Non-Independent Director of Forbion European Acquisition Corp. until October 2023. He was Non-Executive Director of Gyroscope Therapeutics Holdings PLC from March 2021 until February 2022. He served as Senior Life Sciences Trader at Kempen & Co from December 2016 to October 2019, where he served as an Executive Board Member of Kempen's Life Sciences Franchise. In this role, he managed Kempen’s trading portfolio, and was involved in deal structuring and equity capital markets transactions, as well as larger block trades. He served as a Derivatives Trader at Da Vinci Derivatives from July 2016 to December 2016. Prior to that, he served as a Trader at Kempen & Co from August 2013 to July 2016. Mr. Joustra also served as a member of the board of directors of Gyroscope Therapeutics, as a Director at Beacon Therapeutics, as Senior Trader at Kempen, and as an Executive Board member of the life sciences franchise at Kempen. Mr. Joustra received an M.S. in Business Administration from University of Groningen from 2011 to 2013, a B.S.B.A. from University of Groningen from 2011 to 2013, a B.S. in Economics from University of Nebraska, Omaha from 2010 to 2011, a B.S. in International Business & Management from University of Groningen from 2007 to 2011, and an MBA from University of Groningen.
Positions
- Company NameenGene Therapeutics Inc.Stock CodeENGNPositionIndependent Non-Executive DirectorRelated SecuritiesColleagues
- RHRonald H. W. CooperPresident, CEO & Director
- MTMichael Thomas HeffernanIndependent Non-Executive Chairman
- KRKathleen RichtonSenior VP of Finance, Principal Accounting & Financial Officer and Controller
- JCJoan ConnollyChief Technology Officer
- JGJason G. DuncanChief Legal & Administrative Officer
- LSLauren Stival HopferExecutive Director of Investor Relations
- PDPaul D. RobbinsChairman of Scientific Advisory Board
- LSLota S. ZothIndependent Non-Executive Director
